Mode
Text Size
Log in / Sign up

Rapamycin therapy reduced infections and lymph node size in a female child with APDS1

Rapamycin therapy reduced infections and lymph node size in a female child with APDS1
Photo by Faustina Okeke / Unsplash
Key Takeaway
Consider rapamycin as a potential therapy option for APDS1, but recognize that evidence is limited to a single case report.

A single female adopted child was diagnosed with Activated phosphoinositide 3-kinase delta syndrome type I (APDS1) following initial misdiagnosis as lymphoma, cystic fibrosis, or primary ciliary dyskinesia. Genetic testing confirmed the diagnosis via a PIK3CD mutation. The patient was treated with rapamycin-targeted therapy in conjunction with compound sulfamethoxazole within a hospital setting.

Treatment resulted in a significant reduction in the frequency of pulmonary infection episodes. Additionally, the size of enlarged lymph nodes in the neck decreased, and overall control of the condition was deemed effective. No specific numerical data, p-values, or confidence intervals were reported for these outcomes.

Regarding safety, adverse events, serious adverse events, discontinuations, and tolerability were not reported in this case report. The patient remained on the regimen during subsequent follow-up without documented interruptions or adverse reactions.

Limitations of this evidence include the small sample size of one patient and the lack of a control group. Consequently, the findings cannot be generalized to the broader population of patients with APDS1. This report aims to enhance clinicians' understanding of this rare primary immunodeficiency disorder rather than to define standard care.

Study Details

Study typeSystematic review
EvidenceLevel 1
PublishedApr 2026
View Original Abstract ↓
This article presents a case characterized by recurrent pulmonary infections and a poor therapeutic response. Initially, cystic fibrosis (CF) or Primary ciliary dyskinesia was suspected; however, the patient subsequently sought medical attention for a neck mass. The mass was initially misdiagnosed as lymphoma, but a comprehensive examination and assessment ultimately confirmed the diagnosis of activated phosphoinositide 3-kinase delta syndrome type I(APDS1). Through the patient’s tortuous diagnostic journey, this report aims to enhance clinicians’ understanding of this rare primary immunodeficiency disorder. Clinical picture: The patient is a female adopted child who has experienced recurrent lung infections since the age of 6 months. On average, she has required hospitalization 2–3 times annually, with conventional anti-infection treatments proving less effective. Throughout her illness, she was admitted to another hospital for sinusitis and breast cysts, although the specifics of her treatment remain unclear. Subsequently, she presented to our hospital with symptoms of coughing, yellow sputum, and hemoptysis. During her hospitalization, a new neck mass was identified. Key inspection: Imaging assessment revealed a chest CT indicating pulmonary infection and bronchiectasis with mucus plug formation. Neck CT and MRI suggested a potential diagnosis of lymphoma. Pathogen testing through nucleic acid analysis for respiratory pathogens yielded positive results for mycoplasma and adenovirus influenzae. Laboratory and abdominal ultrasound did not identify any abnormalities in the pancreas. A peripheral blood immunological assessment demonstrated significantly diminished cellular and humoral immune functions. Following the resection of the cervical mass, the initial pathological diagnosis was lymphoma; however, tests for T-cell receptor (TCR) and immunoglobulin (IG) gene rearrangements returned negative results. After a multidisciplinary consultation and subsequent pathological re-examination, the diagnosis was revised to infectious mononucleosis. Genetic testing revealed a heterozygous mutation in the PIK3CD gene. Final diagnosis: Activated phosphatidylinositol 3-kinase δ syndrome type I (APDS1). Treatment and prognosis: Following diagnosis, the child was administered rapamycin-targeted therapy in conjunction with compound sulfamethoxazole to prevent infections, with regular monitoring of rapamycin blood concentrations. Subsequent follow-up indicated a significant reduction in the frequency of pulmonary infection episodes, a decrease in the size of the enlarged lymph nodes in the neck, and effective control of the condition.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.